3 completed, 1 recruiting, 1 suspended, 1 withdrawn. 3 Phase 2, 2 Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Withdrawn 1 |
| Phase 1 | 2 | Completed 1, Withdrawn 1 |
| Not applicable | 1 | Recruiting 1 |
Follow PTEN Gene Mutation: new trials by email Literature Review of PTEN Gene Mutation trials Research Report on PTEN Gene Mutation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sirolimus for Improving Social Abilities in People With PTEN Germline Mutations Sirolimus, Placebo - PTEN Gene Mutation, PTEN Hamartoma Tumor Syndrome | Phase 1 / Phase 2 | Withdrawn | Stanford University | 2024-07-01 | 2024-07-10 | |
| Cancer Risk Assessment in Patients With a Constitutional Alteration of the PTEN Gene PTEN Gene Mutation | Suspended | Institut Bergonié | 430 | 2023-06-12 | 2026-05-15 | |
| An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk and An Intervention to Help Patients and Their Primary Care Providers Stay Up-to-date About Uncertain Genetic Test Results Intervention Arm At-risk Relative/ARR Contacts, MyGene Portal, Standard of Care - BRCA1 Mutation, POLD1 Gene Mutation | Not applicable | Recruiting | Memorial Sloan Kettering Cancer Center | 1000 | 2022-12-01 | 2026-08-27 |
| Sirolimus for Cowden Syndrome With Colon Polyposis Sirolimus - PTEN Gene Mutation, PTEN Hamartoma Tumor Syndrome | Phase 2 | Completed | Ohio State University | 5 | 2019-09-16 | 2025-06-10 |
| Access to Resources for Patients With PTEN Hamartoma Tumor Syndrome PTEN Gene Mutation | Completed | University of South Florida | 13 | 2018-05-11 | 2019-10-16 | |
| RAD001 and Neurocognition in PTEN Hamartoma Tumor Syndrome RAD001, Placebo - PTEN Gene Mutation, PTEN Hamartoma Tumor Syndrome | Phase 1 / Phase 2 | Completed | Boston Children's Hospital | 46 | 2017-06-12 | 2025-02-17 |
Hamartoma Syndrome, Multiple (3) · Autistic Disorder (1) · Intellectual Disability (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3) · Genetic Diseases, Inborn (3) · Hamartoma (3) · Neoplasms (3) · Neoplasms, Multiple Primary (3) · Neoplastic Syndromes, Hereditary (3) · Autism Spectrum Disorder (1) · Child Development Disorders, Pervasive (1) · Mental Disorders (1) · Nervous System Diseases (1) · Neurobehavioral Manifestations (1) · Neurodevelopmental Disorders (1) · Neurologic Manifestations (1) · Pathological Conditions, Signs and Symptoms (1) · Signs and Symptoms (1)
Sirolimus (2) · Everolimus (1) · Standard of Care (1)
Boston Children's Hospital (1) · Institut Bergonié (1) · Memorial Sloan Kettering Cancer Center (1) · Ohio State University (1) · Stanford University (1) · University of South Florida (1)
United States (5) · France (1)
Antonio Hardan, MD (1) · Kenneth Offit, MD, MPH (1) · Mustafa Sahin, MD, PhD (1) · Peter P Stanich, MD (1)
U54NS092090 (1)